OPKO Health, Inc. (OPK)
USD 1.46
(-4.58%)
USD 1.46
(-4.58%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -65.51 Million USD | 70.41% |
| 2022 | -270.81 Million USD | -6957.69% |
| 2021 | 83.57 Million USD | -97.55% |
| 2020 | 139.08 Million USD | 295.4% |
| 2019 | -189.64 Million USD | 41.8% |
| 2018 | -68.03 Million USD | 44.03% |
| 2017 | -163.23 Million USD | -764.16% |
| 2016 | 30.46 Million USD | 125.48% |
| 2015 | -87.33 Million USD | 32.44% |
| 2014 | -143.83 Million USD | -359.01% |
| 2013 | -75.2 Million USD | -27.76% |
| 2012 | -25.64 Million USD | -30.37% |
| 2011 | -19.39 Million USD | -135.88% |
| 2010 | -8.55 Million USD | 56.96% |
| 2009 | -22.81 Million USD | 44.66% |
| 2008 | -35.47 Million USD | -115.34% |
| 2007 | -23.91 Million USD | 19911.73% |
| 2006 | -1.11 Million USD | 55.3% |
| 2005 | -181 Thousand USD | -22.14% |
| 2004 | -1.91 Million USD | -41.69% |
| 2003 | -3.67 Million USD | 77.93% |
| 2002 | -8.54 Million USD | 37.73% |
| 2001 | -10.23 Million USD | -26.37% |
| 2000 | -8.31 Million USD | -110.43% |
| 1999 | -3.95 Million USD | -23.47% |
| 1998 | -2.9 Million USD | 3.03% |
| 1997 | -3.2 Million USD | -6.45% |
| 1996 | -2.9 Million USD | -106.67% |
| 1995 | -1.5 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -45.65 Million USD | -15.35% |
| 2024 Q2 | -37.51 Million USD | 143.78% |
| 2023 Q2 | 13.19 Million USD | 248.29% |
| 2023 FY | - USD | 70.41% |
| 2023 Q4 | -43.11 Million USD | 4.39% |
| 2023 Q3 | -45.1 Million USD | -441.72% |
| 2023 Q1 | -8.9 Million USD | 78.45% |
| 2022 Q1 | -46.14 Million USD | 9.16% |
| 2022 FY | - USD | -6957.69% |
| 2022 Q3 | -98.17 Million USD | -38.72% |
| 2022 Q4 | -41.3 Million USD | 57.93% |
| 2022 Q2 | -70.77 Million USD | -53.35% |
| 2021 Q1 | 56.54 Million USD | 10.23% |
| 2021 Q2 | 14.26 Million USD | -74.78% |
| 2021 Q3 | 21.43 Million USD | 50.3% |
| 2021 Q4 | -50.8 Million USD | -336.96% |
| 2021 FY | - USD | -97.55% |
| 2020 FY | - USD | 295.4% |
| 2020 Q4 | 51.3 Million USD | 5.23% |
| 2020 Q2 | 68.78 Million USD | 316.57% |
| 2020 Q3 | 48.74 Million USD | -29.13% |
| 2020 Q1 | -31.76 Million USD | -155.82% |
| 2019 Q3 | -31.43 Million USD | 3.79% |
| 2019 Q1 | -47.7 Million USD | -23.26% |
| 2019 Q2 | -32.67 Million USD | 31.5% |
| 2019 Q4 | 56.9 Million USD | 281.0% |
| 2019 FY | - USD | 41.8% |
| 2018 Q1 | -21.9 Million USD | 81.84% |
| 2018 Q3 | -9.13 Million USD | -170.74% |
| 2018 FY | - USD | 44.03% |
| 2018 Q4 | -38.7 Million USD | -323.88% |
| 2018 Q2 | 12.9 Million USD | 158.93% |
| 2017 Q3 | -43.26 Million USD | -1505.95% |
| 2017 FY | - USD | -764.16% |
| 2017 Q4 | -120.6 Million USD | -178.77% |
| 2017 Q2 | 3.07 Million USD | 129.83% |
| 2017 Q1 | -10.31 Million USD | 66.18% |
| 2016 Q4 | -30.5 Million USD | -5183.33% |
| 2016 Q3 | 600 Thousand USD | -99.14% |
| 2016 Q1 | -2.97 Million USD | 62.32% |
| 2016 Q2 | 69.71 Million USD | 2441.62% |
| 2016 FY | - USD | 125.48% |
| 2015 Q2 | -20.82 Million USD | 58.11% |
| 2015 Q4 | -7.9 Million USD | -133.91% |
| 2015 FY | - USD | 32.44% |
| 2015 Q1 | -49.71 Million USD | -52.97% |
| 2015 Q3 | 23.29 Million USD | 211.88% |
| 2014 Q2 | -15.93 Million USD | 28.39% |
| 2014 FY | - USD | -359.01% |
| 2014 Q4 | -32.5 Million USD | -19.08% |
| 2014 Q1 | -22.24 Million USD | -295.34% |
| 2014 Q3 | -27.29 Million USD | -71.33% |
| 2013 Q2 | -3.83 Million USD | -1084.1% |
| 2013 Q3 | -22.68 Million USD | -491.17% |
| 2013 Q1 | 390 Thousand USD | 105.17% |
| 2013 FY | - USD | -27.76% |
| 2013 Q4 | -5.62 Million USD | 75.2% |
| 2012 Q1 | -6.49 Million USD | 18.56% |
| 2012 Q2 | -5.87 Million USD | 9.5% |
| 2012 Q3 | -6.09 Million USD | -3.81% |
| 2012 FY | - USD | -30.37% |
| 2012 Q4 | -7.54 Million USD | -23.64% |
| 2011 Q3 | -4.18 Million USD | -6.35% |
| 2011 FY | - USD | -135.88% |
| 2011 Q4 | -7.97 Million USD | -90.35% |
| 2011 Q1 | -4.12 Million USD | -1411.72% |
| 2011 Q2 | -3.93 Million USD | 4.58% |
| 2010 Q2 | -4.14 Million USD | -50.42% |
| 2010 Q1 | -2.75 Million USD | -59.99% |
| 2010 FY | - USD | 56.96% |
| 2010 Q4 | -273 Thousand USD | 94.89% |
| 2010 Q3 | -5.34 Million USD | -28.98% |
| 2009 Q3 | -4.93 Million USD | -15.08% |
| 2009 Q4 | -1.72 Million USD | 65.07% |
| 2009 Q1 | -7.66 Million USD | 30.14% |
| 2009 FY | - USD | 44.66% |
| 2009 Q2 | -4.28 Million USD | 44.12% |
| 2008 Q4 | -10.97 Million USD | -53.02% |
| 2008 FY | - USD | -115.34% |
| 2008 Q1 | -9.91 Million USD | -22.28% |
| 2008 Q2 | -7.17 Million USD | 27.66% |
| 2008 Q3 | -7.17 Million USD | -0.01% |
| 2007 Q1 | 487.52 Million USD | 102306.92% |
| 2007 Q4 | -8.1 Million USD | -459.9% |
| 2007 Q3 | 2.25 Million USD | 121.45% |
| 2007 Q2 | -10.5 Million USD | -102.15% |
| 2007 FY | - USD | 19911.73% |
| 2006 Q4 | -477 Thousand USD | -21.68% |
| 2006 FY | - USD | 55.3% |
| 2006 Q1 | -333 Thousand USD | 2.06% |
| 2006 Q2 | -170 Thousand USD | 48.95% |
| 2006 Q3 | -392 Thousand USD | -130.59% |
| 2005 Q3 | -1.25 Million USD | -136.21% |
| 2005 FY | - USD | -22.14% |
| 2005 Q4 | -340 Thousand USD | 72.99% |
| 2005 Q1 | -371 Thousand USD | -14.86% |
| 2005 Q2 | -533 Thousand USD | -43.67% |
| 2004 FY | - USD | -41.69% |
| 2004 Q4 | -323 Thousand USD | 24.53% |
| 2004 Q3 | -428 Thousand USD | 27.21% |
| 2004 Q2 | -588 Thousand USD | 26.22% |
| 2004 Q1 | -797 Thousand USD | -131.1% |
| 2003 Q2 | -1.83 Million USD | -66.21% |
| 2003 Q3 | -1.55 Million USD | 7.2% |
| 2003 Q4 | 737 Thousand USD | 274.35% |
| 2003 Q1 | -1.02 Million USD | -6253.33% |
| 2003 FY | - USD | 77.93% |
| 2002 Q4 | -2.02 Million USD | 99.44% |
| 2002 Q2 | -1.95 Million USD | -4.49% |
| 2002 Q1 | -1.86 Million USD | 20.79% |
| 2002 Q3 | -2.7 Million USD | -38.21% |
| 2002 FY | - USD | 37.73% |
| 2001 Q3 | -2.84 Million USD | 12.81% |
| 2001 FY | - USD | -26.37% |
| 2001 Q1 | -1.71 Million USD | 4.51% |
| 2001 Q2 | -3.26 Million USD | -90.26% |
| 2001 Q4 | -2.36 Million USD | 16.98% |
| 2000 Q1 | -2.45 Million USD | -133.87% |
| 2000 Q4 | -1.79 Million USD | 24.41% |
| 2000 Q3 | -2.37 Million USD | -41.09% |
| 2000 Q2 | -1.68 Million USD | 31.49% |
| 2000 FY | - USD | -110.43% |
| 1999 Q2 | -750 Thousand USD | 46.15% |
| 1999 Q1 | -1.3 Million USD | -30.0% |
| 1999 FY | - USD | -23.47% |
| 1999 Q3 | -900 Thousand USD | -28.57% |
| 1999 Q4 | -1.05 Million USD | -16.78% |
| 1998 FY | - USD | 3.03% |
| 1998 Q3 | -1.2 Million USD | -200.0% |
| 1998 Q2 | -400 Thousand USD | 42.86% |
| 1998 Q1 | -700 Thousand USD | 12.5% |
| 1998 Q4 | -1 Million USD | 16.67% |
| 1997 Q1 | -600 Thousand USD | 25.0% |
| 1997 Q2 | -600 Thousand USD | 0.0% |
| 1997 Q3 | -900 Thousand USD | -50.0% |
| 1997 Q4 | -800 Thousand USD | 11.11% |
| 1997 FY | - USD | -6.45% |
| 1996 Q2 | -700 Thousand USD | 0.0% |
| 1996 Q1 | -700 Thousand USD | 0.0% |
| 1996 FY | - USD | -106.67% |
| 1996 Q3 | -700 Thousand USD | 0.0% |
| 1996 Q4 | -800 Thousand USD | -14.29% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 44.273% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -583.096% |
| Aspira Women's Health Inc. | -16.49 Million USD | -297.283% |
| Biodesix, Inc. | -37.1 Million USD | -76.579% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -2536.288% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -758.741% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -758.741% |
| Bionano Genomics, Inc. | -213.6 Million USD | 69.328% |
| CareDx, Inc | -89.65 Million USD | 26.926% |
| Check-Cap Ltd. | -17.64 Million USD | -271.216% |
| Castle Biosciences, Inc. | -45.02 Million USD | -45.514% |
| DarioHealth Corp. | -53.49 Million USD | -22.474% |
| Exact Sciences Corporation | 41.87 Million USD | 256.452% |
| Fulgent Genetics, Inc. | -46.55 Million USD | -40.737% |
| Guardant Health, Inc. | -433.3 Million USD | 84.88% |
| ICON Public Limited Company | 1.63 Billion USD | 104.015% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 105.38% |
| Illumina, Inc. | -608 Million USD | 89.224% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -643.595% |
| iSpecimen Inc. | -9.1 Million USD | -619.662% |
| Standard BioTools Inc. | -54.45 Million USD | -20.308% |
| MDxHealth SA | -30.46 Million USD | -115.032% |
| 23andMe Holding Co. | -291.87 Million USD | 77.553% |
| Medpace Holdings, Inc. | 363.15 Million USD | 118.041% |
| Myriad Genetics, Inc. | -67.8 Million USD | 3.369% |
| Mainz Biomed B.V. | -25.01 Million USD | -161.947% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -569.569% |
| NeoGenomics, Inc. | -17.6 Million USD | -272.102% |
| Neogen Corporation | 182.59 Million USD | 135.88% |
| Inotiv, Inc. | -26.5 Million USD | -147.174% |
| Natera, Inc. | -383.27 Million USD | 82.906% |
| OpGen, Inc. | -29.51 Million USD | -122.005% |
| Psychemedics Corporation | -251 Thousand USD | -26001.992% |
| Prenetics Global Limited | -47.89 Million USD | -36.788% |
| Prenetics Global Limited | -47.89 Million USD | -36.788% |
| Precipio, Inc. | -4.31 Million USD | -1417.277% |
| Personalis, Inc. | -96.8 Million USD | 32.323% |
| RadNet, Inc. | 292.78 Million USD | 122.377% |
| Sera Prognostics, Inc. | -35.28 Million USD | -85.666% |
| Sotera Health Company | 514.14 Million USD | 112.743% |
| Neuronetics, Inc. | -22.75 Million USD | -187.869% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -3783.58% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -3783.58% |
| Trinity Biotech plc | -24.09 Million USD | -171.873% |
| T2 Biosystems, Inc. | -43.87 Million USD | -49.324% |
| Twist Bioscience Corporation | -176.7 Million USD | 62.924% |
| Exagen Inc. | -19.15 Million USD | -242.067% |